SCHEMBL10148083

SCHEMBL10148083

O=C(O)c1ccc(F)c(OCC2CCC2)c1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 1/20 0.54
TTR P02766 3/20 0.48
RBP4 P02753 1/20 0.48
PARP10 Q53GL7 5/20 0.48
PARP15 Q460N3 4/20 0.48
PARP2 Q9UGN5 1/20 0.48
XDH P47989 1/20 0.46
PDE4B Q07343 2/20 0.45
PDE4A P27815 1/20 0.45
PDE4C Q08493 1/20 0.45
PDE4D Q08499 1/20 0.45
ALB P02768 1/20 0.44
PTGER1 P34995 2/20 0.43
KDM4C Q9H3R0 1/20 0.43
NR1H4 Q96RI1 1/20 0.43
FABP4 P15090 1/20 0.43
FABP5 Q01469 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12420683 0.96 XDH (0.50) MAP4K4TTRRBP4PARP10PARP15
SCHEMBL662159 0.94 TTR (0.50) MAP4K4TTRRBP4PARP10PARP15
SCHEMBL10148081 0.89 MAP4K4 (0.54) MAP4K4TTRRBP4PARP10PARP15
SCHEMBL24968525 0.87 KDM4C (0.53) MAP4K4TTRRBP4PDE4BPDE4A
SCHEMBL15968784 0.82 LMNA (0.55) MAP4K4TTRRBP4PARP10PARP15
SCHEMBL6940040 0.82 TSHR (0.62) MAP4K4TTRXDHPDE4BPDE4A
SCHEMBL7374749 0.81 PDE4B (0.69) MAP4K4PDE4BPDE4APDE4CPDE4D
SCHEMBL13806376 0.81 PARP10 (0.46) PARP10PARP15PARP2XDHPDE4B
SCHEMBL18374473 0.81 PDE4B (0.49) PARP10PARP15PARP2PDE4BPDE4A
SCHEMBL28034346 0.80 PDE4B (0.53) MAP4K4PARP10PARP15PARP2XDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120046292-A1 DIACYLETHYLENEDIAMINE COMPOUND ASTELLAS PHARMA INC. (JP) 2012-02-23 US disclosed
US-20120046292-A1 DIACYLETHYLENEDIAMINE COMPOUND ASTELLAS PHARMA INC. (JP) 2012-02-23 US disclosed
WO-2010122968-A1 DIACYLETHYLENEDIAMINE COMPOUND アステラス製薬株式会社 (JP) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046292-A1 DIACYLETHYLENEDIAMINE COMPOUND DGAT1, DGAT2, DIMT1 MAP4K4 3718/4885TTR 4836/4885RBP4 3074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.